Your Messages Inbox
Your Article Summary
See Latest ArticlesBioMimetic Therapeutics, Inc. Announces an $8 Million Private Placement; Company Intends to Commence Rights Offering
BioMimetic Therapeutics, 05/04/09
BioMimetic Therapeutics, Inc. announced that on April 2009, the Company entered into a definitive purchase agreement with InterWest Partners X, LP, an affiliate of InterWest Partners, one of the Company's existing stockholders, for the private placement of 941,177 shares of its common stock at a price of $8.50 per share. The purchase price represents a significant premium to the market price of the Common Stock on the date of execution of the purchase agreement. The transaction is expected to raise approximately $8.0 million in gross proceeds. The closing of the financing is expected to occur as soon as practicable, subject to the satisfaction of customary closing conditions.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN (pralatrexate injection)
Allos Therapeutics, 12/07/09
Conclusion of a license agreement between BioComber and Chugai on patents related to PURESYSTEM
Chugai Pharmaceutical Co., 12/07/09
Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
BayNews International, 12/04/09
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Bristol-Myers Squibb and Mead Johnson Announce Amendment and Extension of Exchange Offer
Bristol Myers-Squibb Company, 12/07/09
Prodesses ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Gen-Probe, 12/03/09
Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
Shire, 12/03/09
Article Search
Sponsor